Arcturus Therapeutics Holdings Inc. (ARCT) stock
ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3010% below fair value
$7.97−0.34 (-4.09%)
Close on Nov 17, 2026Market cap $226.53MP/E –Yield –
Arcturus Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Arcturus Therapeutics's pe ratio was 8.9× on Jan 31, 2024.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Jan 31, 2024 | 8.9× | +0.4 |
| 2023 | Dec 29, 2023 | 8.5× | – |
See a number that looks wrong?